Precision Oncology Market Size, Share, Growth Opportunity Analysis Report by Technology (Genomics & Sequencing (NGS), Proteomics, Transcriptomics, Epigenomics, CRISPR & Gene Editing, Digital Pathology & AI-based Imaging, Biomarker Testing Platforms and Others), Product & Service, Cancer Type, Biomarker Type, Delivery Model, Application, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035.
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Precision Oncology Market Size, Share, and Growth
The growth of global precision oncology market is likely to create a significant opportunity of USD 178.1 Billion during the forecasting period, 2025-2035. The key drivers of this global precision oncology market are the rapid advancement in genomic sequencing and the expansion of targeted therapy pipelines.
In April 2025, Thermo Fisher Scientific launched its Oncomine Comprehensive Multi‑Omics Assay, a next-generation test combining DNA, RNA, and protein profiling to support deeper insights into tumor biology for precision oncology applications. CEO Marc N. Casper stated that the launch reflects the company’s commitment to expanding multi-omics capabilities for more accurate and personalized cancer treatment strategies.
Advances in NGS are empowering the quick and inexpensive identifications of mutations specific to a cancer, i.e., the case with Illumina's planned launch of an ultra-fast sequencing platform in 2024. The therapy landscape is shifting further with the advent of targeted biologics; i.e., FDA approval in June of 2025 of Datopotamab Deruxtecan, an agent directed against TROP2, for the treatment of patients with advanced non-small cell lung cancer issued to AstraZeneca and Daiichi Sankyo. Such factors bring in time for moving ahead in personalized treatments in cancer, which push for a strong global market growth for precision oncology.
Some opportunities in precision oncology are companion diagnostics utilized to validate targeted therapies, AI-assisted clinical decision support systems, and liquid biopsy technologies for non-invasive monitoring of cancer. Most of these segments work with precision in diagnosis, treatment planning, and follow-up of the disease, complementing the power in oncology. All of these opportunities will further enable the creation of a comprehensive precision medicine ecosystem, amplifying the impact and accessibility of precision oncology.
Precision Oncology Market Dynamics and Trends
Driver: Integration of AI in Genomic Data Interpretation
- The growing influence of AI toward accelerated interpretation of genomic data is powering precision oncology markets globally. AI platforms are being employed increasingly to analyze complex and noisy datasets from tumor sequencing to uncover actionable mutations, drug targets, and resistance mechanisms faster and more accurately, so the oncologists can make treatment decisions in a timely manner tailored to specific Cases.
- In April 2025, Tempus launched Tempus Edge, the AI-enabled diagnostic platform that applies machine learning technology to find the most suitable treatment regimens on the basis of genomic and clinical data. The platform has been adopted by several leading cancer centers in the U.S., slashing almost 40% off the time from diagnosis to therapy selection. Not only does this have implications on the clinical decision-making process, but the growing use of AI diagnostic platforms has also facilitated precision oncology in community healthcare settings.
- Hence, the AI is simplifying complex diagnostics that have varied adoption across the systems of precision oncology.
Restraint: High Cost and Limited Reimbursement for Advanced Testing
- Costly comprehensive genomic profiling and disparate reimbursement policies in different regions arise as one major restraint in the precision oncology market. Most of these multi-gene panels and whole-genome sequencing tests are very expensive, usually charging anywhere beyond $3,000-$5,000, so much that many patients and even smaller healthcare systems simply cannot afford the tests. Since no standard reimbursement policies exist, payers refuse to reimburse for advanced diagnostics until a strong grappling with clinical utility unfolds.
- For example, Foundation Medicine (Roche Subsidiary) reported delayed uptake of its Foundation One CDx in some European markets on account of reimbursement rejections by public health agencies in February 2025. This financial barrier greatly restricts the implementation of precision diagnostics into regular practice and patient access to tailored therapeutics. Until payers include the long-term cost benefits of precision care, this hindrance to market growth will remain.
- The high costs of testing and reimbursement voids that impede scalability have consequently slowed adoption of precision oncology in cost-sensitive markets.
Opportunity: Expansion of Tumor-Agnostic Therapies
- Tumor-agnostic treatment presents one of the greatest opportunities in the current landscape of precision oncology. Such treatments are offered for cancers that have certain specified genetic aberrations and not for location-based tumors, thereby liberating treatments into a broad spectrum that involves several cancer types, hence creating a larger patient plasma to be eligible for admission and possible treatments with streamlined development of drugs.
- In April 2025, the Bayer and Merck & Co. collaborations announce Phase III results indicative of positive results for NTRK gene fusion-positive tumors. Such results reiterate the clinical value of tumor-agnostic drug development. With accelerating pathways from agencies like FDA and EMA for such therapies, companies now are increasingly investing in biomarker-based pipelines. As further diagnostics and genetic testing gain wider acceptance, the tumor-agnostic therapy market will grow, thereby granting a great space for innovation.
- The development of tumor-agnostic drugs expands their therapeutic reach, creating high-value growth potential in cancer subclasses within precision oncology.
Key Trend: Rise of Multi-Omics in Personalized Cancer Treatment
- One of the current trends in precision oncology is the growing adoption of multi-omics approaches, carrying genomics, proteomics, transcriptomics, and metabolomics in tandem to generate a more penetrating view into the biology of a patient's tumor. These datasets then set the framework for better treatment prediction, discovery of new biomarkers, and insight into tumor evolution.
- In January 2025, Thermo Fisher Scientific launched the Oncomine Comprehensive Multi-Omics Assay with a promise for simultaneous detection of DNA-, RNA-, and protein-level alterations in a single workflow. Early adopters at some academic cancer centers seem to be using it to stratify better patients for clinical trials. Multi-omics is trying to close the gap between molecular data and therapeutic response, especially in difficult-to-treat cancers or in rare ones. With further improvements in ease-of-use and decreases in costs, it is expected that this trend will shift away from research settings and into clinical routine.
- Multi-omics is providing additional in-depth and actionable biological insights to change the foundation of personalized oncology and expedite next-gene therapy development.
Precision Oncology Market Analysis and Segmental Data
Based on Technology, the Genomics & Sequencing Segment Retains the Largest Share
- The genomics & sequencing segment holds major share ~44% in the global precision oncology market. Genomics and sequencing constitute the biggest revenue subsegment in precision oncology due to their pivotal roles in diagnosing actionable mutations in a plethora of cancer types and thus fine-tuning treatment decisions. With the advent of NGS, broadband cheap and quick whole-genome analysis took less than 24 hours at an average cost of $1,500, spearheading greater adoption in the academic and community settings. For example, in March 2025, Illumina launched its NovaSeq X Plus instrument offering an ultra-high throughput sequencing platform operating at 30% lower cost and analysis time, thus enabling faster tumor profiling on a larger scale.
- Due to enhanced accessibility going side by-side with rapid genomic testing, genomics has become the cornerstone of precision oncology, proliferating the formation of this market and greater integration into allopathic cancer treatment.
North America Dominates Global Precision Oncology Market in 2024 and Beyond
- North America holds the highest demand for the precision oncology ecosystem because of strong R&D infrastructure, early adoption of advanced genomic technologies, and widespread availability of targeted therapies. The region sees the advantage of huge national initiatives such as the Cancer Moonshot program working towards a rapid acceleration of genomic research and clinical applications. The multi-gene companion diagnostic approval gained its FDA clearance in August 2024 for Illumina's TruSight Oncology test and further aided in enabling personalized treatment decisions across multiple cancers. Alongside these advances and a strong reimbursement environment, the dominance of North America will likely continue into the future with very high healthcare spending.
- Also present in this region are leading pharmaceutical and biotechnology companies, stellar clinical trial networks, and established cancer centers, all of which ensure the strong and rapid pace of adoption in precision medicine. Cooperation between diagnostic developers and therapy manufacturers is also relatively frequent within this region, which serves to contribute to the innovation of biomarker-guided treatment. Hence, North America continues to maintain a global leadership position in precision oncology.
- Advanced infrastructure and innovation-driven policies firmly establish North America as the growth hub of the precision oncology market.
Precision Oncology Market Ecosystem
Key players in the global precision oncology market include prominent companies such as Illumina, Inc., F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific, Agilent Technologies, Bio‑Rad Laboratories and Other Key Players.
The worldwide market for precision oncology is moderately fragmented, with Tier 1 players Roche, AstraZeneca, Novartis, Pfizer, and Illumina holding strong positions through integrated drug–diagnostic portfolios, while the Tier 2 players Guardant Health, Foundation Medicine, Qiagen, and Agilent, and Tier 3 players Natera, Myriad Genetics, Invitae, and Caris Life Sciences specialize in niche technologies and testing services. Buyer concentration is moderate-to-high, as hospitals, cancer centers, and third-party payers demand that providers be cost-effective and show validated outcomes. The supplier concentration is moderate, as these advanced genomics and bioinformatics and consumables are provided by a handful of competitive technology vendors.
Recent Development and Strategic Overview:
- In June 2025, in a licensing and option agreement worth up to $750 million for molecular glue degraders for cancer indication enabling selective targeting of CDK2 in solid tumors, the movement showed that they are moving towards more precise, protein degrader therapies.
- In June 2025, US FDA has approved Datroway for advanced non-small cell lung cancer, growing the precision oncology franchise and underlining the value of biomarker-driven ADCs in very hard-to-treat disease settings.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 139.4 Bn |
|
Market Forecast Value in 2035 |
USD 317.5 Bn |
|
Growth Rate (CAGR) |
7.8% |
|
Forecast Period |
2025 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
|
|
|
Precision Oncology Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
By Technology |
|
|
By Product & Service |
|
|
By Cancer Type |
|
|
By Biomarker Type |
|
|
By Delivery Model |
|
|
By Application |
|
|
By End User |
|
Frequently Asked Questions
The global precision oncology market was valued at USD 139.4 Bn in 2025.
The global precision oncology market industry is expected to grow at a CAGR of 7.8% from 2025 to 2035.
The key factors driving demand in the precision oncology market include the rising global cancer burden, growing availability of genomic testing, and the increasing success of targeted therapies and companion diagnostics. Advancements in next-generation sequencing, regulatory support for biomarker-based treatments, and personalized treatment approaches are further accelerating market adoption across diverse cancer types.
The genomics & sequencing segment leads demand in precision oncology due to its critical role in identifying actionable mutations across diverse cancer types, enabling tailored treatment decisions.
The India is among the fastest-growing countries globally.
Agilent Technologies, AstraZeneca plc, Bio-Rad Laboratories, Bristol Myers Squibb, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine (Roche), Grail (a subsidiary of Illumina), Guardant Health, Illumina, Inc., Invitae Corporation, Merck & Co., Inc., Myriad Genetics, Natera, Inc., Novartis AG, Pfizer Inc., Qiagen N.V., Roche Diagnostics, Thermo Fisher Scientific and Other Key Players.
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Precision Oncology Market Outlook
- 2.1.1. Precision Oncology Market Size (Value - US$ Billion), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End Use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Precision Oncology Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Overview, 2025
- 3.1.1. Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising prevalence of cancer and demand for personalized treatment approaches
- 4.1.1.2. Advancements in next-generation sequencing (NGS) and genomic profiling technologies
- 4.1.1.3. Increasing approvals of biomarker-driven targeted therapies and companion diagnostics
- 4.1.2. Restraints
- 4.1.2.1. High cost of genomic testing and limited reimbursement policies in several regions
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis/ Ecosystem Analysis
- 4.4.1. R&D and Genomic Technology Development
- 4.4.2. Diagnostic and Therapeutic Manufacturing
- 4.4.3. Clinical Implementation
- 4.4.4. Regulatory and Reimbursement Framework
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Precision Oncology Market Demand
- 4.9.1. Historical Market Size - in Value (Value - US$ Billion), 2021-2024
- 4.9.2. Current and Future Market Size - in Value (Value - US$ Billion), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Precision Oncology Market Analysis, by Technology
- 6.1. Key Segment Analysis
- 6.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Technology, 2021-2035
- 6.2.1. Genomics & Sequencing (NGS)
- 6.2.2. Proteomics
- 6.2.3. Transcriptomics
- 6.2.4. Epigenomics
- 6.2.5. CRISPR & Gene Editing
- 6.2.6. Digital Pathology & AI-based Imaging
- 6.2.7. Biomarker Testing Platforms
- 6.2.8. Others
- 7. Global Precision Oncology Market Analysis, by Product & Service
- 7.1. Key Segment Analysis
- 7.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Product & Service, 2021-2035
- 7.2.1. Consumables & Reagents
- 7.2.2. Instruments & Platforms
- 7.2.3. Companion Diagnostics
- 7.2.4. Bioinformatics Solutions
- 7.2.5. Services (e.g., sequencing, data analysis, genetic counseling)
- 7.2.6. Others
- 8. Global Precision Oncology Market Analysis, by Cancer Type
- 8.1. Key Segment Analysis
- 8.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Cancer Type, 2021-2035
- 8.2.1. Breast Cancer
- 8.2.2. Lung Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Prostate Cancer
- 8.2.5. Melanoma
- 8.2.6. Hematologic Malignancies (e.g., leukemia, lymphoma)
- 8.2.7. Other Solid Tumors (e.g., pancreatic, gastric, ovarian)
- 9. Global Precision Oncology Market Analysis, by Biomarker Type
- 9.1. Key Segment Analysis
- 9.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Biomarker Type, 2021-2035
- 9.2.1. Genetic Biomarkers
- 9.2.2. Protein Biomarkers
- 9.2.3. Circulating Tumor DNA (ctDNA)
- 9.2.4. Circulating Tumor Cells (CTCs)
- 9.2.5. RNA Biomarkers
- 9.2.6. Epigenetic Markers
- 9.2.7. Others
- 10. Global Precision Oncology Market Analysis, by Delivery Model
- 10.1. Key Segment Analysis
- 10.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Delivery Model, 2021-2035
- 10.2.1. Laboratory Developed Tests (LDTs)
- 10.2.2. FDA-Approved Companion Diagnostics (CDx)
- 10.2.3. At-Home Genetic Testing Kits
- 10.2.4. Cloud-based Precision Oncology Platforms
- 10.2.5. Others
- 11. Global Precision Oncology Market Analysis, by Application
- 11.1. Key Segment Analysis
- 11.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Application, 2021-2035
- 11.2.1. Biomarker Discovery
- 11.2.2. Drug Development & Targeted Therapy
- 11.2.3. Clinical Diagnostics
- 11.2.4. Prognostics & Risk Assessment
- 11.2.5. Theranostics (therapy + diagnostics)
- 11.2.6. Monitoring & Recurrence Detection
- 11.2.7. Others
- 12. Global Precision Oncology Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by End User, 2021-2035
- 12.2.1. Hospitals & Clinics
- 12.2.2. Academic & Research Institutes
- 12.2.3. Pharmaceutical & Biotechnology Companies
- 12.2.4. Diagnostic Laboratories
- 12.2.5. Contract Research Organizations (CROs)
- 12.2.6. Others
- 13. Global Precision Oncology Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Precision Oncology Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Precision Oncology Market Size Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 14.3.1. Technology
- 14.3.2. Product & Service
- 14.3.3. Cancer Type
- 14.3.4. Biomarker Type
- 14.3.5. Delivery Model
- 14.3.6. Application
- 14.3.7. End User
- 14.3.8. Country
- 14.3.8.1. USA
- 14.3.8.2. Canada
- 14.3.8.3. Mexico
- 14.4. USA Precision Oncology Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Technology
- 14.4.3. Product & Service
- 14.4.4. Cancer Type
- 14.4.5. Biomarker Type
- 14.4.6. Delivery Model
- 14.4.7. Application
- 14.4.8. End User
- 14.5. Canada Precision Oncology Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Technology
- 14.5.3. Product & Service
- 14.5.4. Cancer Type
- 14.5.5. Biomarker Type
- 14.5.6. Delivery Model
- 14.5.7. Application
- 14.5.8. End User
- 14.6. Mexico Precision Oncology Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Technology
- 14.6.3. Product & Service
- 14.6.4. Cancer Type
- 14.6.5. Biomarker Type
- 14.6.6. Delivery Model
- 14.6.7. Application
- 14.6.8. End User
- 15. Europe Precision Oncology Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 15.3.1. Technology
- 15.3.2. Product & Service
- 15.3.3. Cancer Type
- 15.3.4. Biomarker Type
- 15.3.5. Delivery Model
- 15.3.6. Application
- 15.3.7. End User
- 15.3.8. Country
- 15.3.8.1. Germany
- 15.3.8.2. United Kingdom
- 15.3.8.3. France
- 15.3.8.4. Italy
- 15.3.8.5. Spain
- 15.3.8.6. Netherlands
- 15.3.8.7. Nordic Countries
- 15.3.8.8. Poland
- 15.3.8.9. Russia & CIS
- 15.3.8.10. Rest of Europe
- 15.4. Germany Precision Oncology Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Technology
- 15.4.3. Product & Service
- 15.4.4. Cancer Type
- 15.4.5. Biomarker Type
- 15.4.6. Delivery Model
- 15.4.7. Application
- 15.4.8. End User
- 15.5. United Kingdom Precision Oncology Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Technology
- 15.5.3. Product & Service
- 15.5.4. Cancer Type
- 15.5.5. Biomarker Type
- 15.5.6. Delivery Model
- 15.5.7. Application
- 15.5.8. End User
- 15.6. France Precision Oncology Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Technology
- 15.6.3. Product & Service
- 15.6.4. Cancer Type
- 15.6.5. Biomarker Type
- 15.6.6. Delivery Model
- 15.6.7. Application
- 15.6.8. End User
- 15.7. Italy Precision Oncology Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Technology
- 15.7.3. Product & Service
- 15.7.4. Cancer Type
- 15.7.5. Biomarker Type
- 15.7.6. Delivery Model
- 15.7.7. Application
- 15.7.8. End User
- 15.8. Spain Precision Oncology Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Technology
- 15.8.3. Product & Service
- 15.8.4. Cancer Type
- 15.8.5. Biomarker Type
- 15.8.6. Delivery Model
- 15.8.7. Application
- 15.8.8. End User
- 15.9. Netherlands Precision Oncology Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Technology
- 15.9.3. Product & Service
- 15.9.4. Cancer Type
- 15.9.5. Biomarker Type
- 15.9.6. Delivery Model
- 15.9.7. Application
- 15.9.8. End User
- 15.10. Nordic Countries Precision Oncology Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Technology
- 15.10.3. Product & Service
- 15.10.4. Cancer Type
- 15.10.5. Biomarker Type
- 15.10.6. Delivery Model
- 15.10.7. Application
- 15.10.8. End User
- 15.11. Poland Precision Oncology Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Technology
- 15.11.3. Product & Service
- 15.11.4. Cancer Type
- 15.11.5. Biomarker Type
- 15.11.6. Delivery Model
- 15.11.7. Application
- 15.11.8. End User
- 15.12. Russia & CIS Precision Oncology Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Technology
- 15.12.3. Product & Service
- 15.12.4. Cancer Type
- 15.12.5. Biomarker Type
- 15.12.6. Delivery Model
- 15.12.7. Application
- 15.12.8. End User
- 15.13. Rest of Europe Precision Oncology Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Technology
- 15.13.3. Product & Service
- 15.13.4. Cancer Type
- 15.13.5. Biomarker Type
- 15.13.6. Delivery Model
- 15.13.7. Application
- 15.13.8. End User
- 16. Asia Pacific Precision Oncology Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 16.3.1. Technology
- 16.3.2. Product & Service
- 16.3.3. Cancer Type
- 16.3.4. Biomarker Type
- 16.3.5. Delivery Model
- 16.3.6. Application
- 16.3.7. End User
- 16.3.8. Country
- 16.3.8.1. China
- 16.3.8.2. India
- 16.3.8.3. Japan
- 16.3.8.4. South Korea
- 16.3.8.5. Australia and New Zealand
- 16.3.8.6. Indonesia
- 16.3.8.7. Malaysia
- 16.3.8.8. Thailand
- 16.3.8.9. Vietnam
- 16.3.8.10. Rest of Asia Pacific
- 16.4. China Precision Oncology Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Technology
- 16.4.3. Product & Service
- 16.4.4. Cancer Type
- 16.4.5. Biomarker Type
- 16.4.6. Delivery Model
- 16.4.7. Application
- 16.4.8. End User
- 16.5. India Precision Oncology Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Technology
- 16.5.3. Product & Service
- 16.5.4. Cancer Type
- 16.5.5. Biomarker Type
- 16.5.6. Delivery Model
- 16.5.7. Application
- 16.5.8. End User
- 16.6. Japan Precision Oncology Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Technology
- 16.6.3. Product & Service
- 16.6.4. Cancer Type
- 16.6.5. Biomarker Type
- 16.6.6. Delivery Model
- 16.6.7. Application
- 16.6.8. End User
- 16.7. South Korea Precision Oncology Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Technology
- 16.7.3. Product & Service
- 16.7.4. Cancer Type
- 16.7.5. Biomarker Type
- 16.7.6. Delivery Model
- 16.7.7. Application
- 16.7.8. End User
- 16.8. Australia and New Zealand Precision Oncology Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Technology
- 16.8.3. Product & Service
- 16.8.4. Cancer Type
- 16.8.5. Biomarker Type
- 16.8.6. Delivery Model
- 16.8.7. Application
- 16.8.8. End User
- 16.9. Indonesia Precision Oncology Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Technology
- 16.9.3. Product & Service
- 16.9.4. Cancer Type
- 16.9.5. Biomarker Type
- 16.9.6. Delivery Model
- 16.9.7. Application
- 16.9.8. End User
- 16.10. Malaysia Precision Oncology Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Technology
- 16.10.3. Product & Service
- 16.10.4. Cancer Type
- 16.10.5. Biomarker Type
- 16.10.6. Delivery Model
- 16.10.7. Application
- 16.10.8. End User
- 16.11. Thailand Precision Oncology Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Technology
- 16.11.3. Product & Service
- 16.11.4. Cancer Type
- 16.11.5. Biomarker Type
- 16.11.6. Delivery Model
- 16.11.7. Application
- 16.11.8. End User
- 16.12. Vietnam Precision Oncology Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Technology
- 16.12.3. Product & Service
- 16.12.4. Cancer Type
- 16.12.5. Biomarker Type
- 16.12.6. Delivery Model
- 16.12.7. Application
- 16.12.8. End User
- 16.13. Rest of Asia Pacific Precision Oncology Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Technology
- 16.13.3. Product & Service
- 16.13.4. Cancer Type
- 16.13.5. Biomarker Type
- 16.13.6. Delivery Model
- 16.13.7. Application
- 16.13.8. End User
- 17. Middle East Precision Oncology Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 17.3.1. Technology
- 17.3.2. Product & Service
- 17.3.3. Cancer Type
- 17.3.4. Biomarker Type
- 17.3.5. Delivery Model
- 17.3.6. Application
- 17.3.7. End User
- 17.3.8. Country
- 17.3.8.1. Turkey
- 17.3.8.2. UAE
- 17.3.8.3. Saudi Arabia
- 17.3.8.4. Israel
- 17.3.8.5. Rest of Middle East
- 17.4. Turkey Precision Oncology Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Technology
- 17.4.3. Product & Service
- 17.4.4. Cancer Type
- 17.4.5. Biomarker Type
- 17.4.6. Delivery Model
- 17.4.7. Application
- 17.4.8. End User
- 17.5. UAE Precision Oncology Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Technology
- 17.5.3. Product & Service
- 17.5.4. Cancer Type
- 17.5.5. Biomarker Type
- 17.5.6. Delivery Model
- 17.5.7. Application
- 17.5.8. End User
- 17.6. Saudi Arabia Precision Oncology Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Technology
- 17.6.3. Product & Service
- 17.6.4. Cancer Type
- 17.6.5. Biomarker Type
- 17.6.6. Delivery Model
- 17.6.7. Application
- 17.6.8. End User
- 17.7. Israel Precision Oncology Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Technology
- 17.7.3. Product & Service
- 17.7.4. Cancer Type
- 17.7.5. Biomarker Type
- 17.7.6. Delivery Model
- 17.7.7. Application
- 17.7.8. End User
- 17.8. Rest of Middle East Precision Oncology Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Technology
- 17.8.3. Product & Service
- 17.8.4. Cancer Type
- 17.8.5. Biomarker Type
- 17.8.6. Delivery Model
- 17.8.7. Application
- 17.8.8. End User
- 18. Africa Precision Oncology Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 18.3.1. Technology
- 18.3.2. Product & Service
- 18.3.3. Cancer Type
- 18.3.4. Biomarker Type
- 18.3.5. Delivery Model
- 18.3.6. Application
- 18.3.7. End User
- 18.3.8. Country
- 18.3.8.1. South Africa
- 18.3.8.2. Egypt
- 18.3.8.3. Nigeria
- 18.3.8.4. Algeria
- 18.3.8.5. Rest of Africa
- 18.4. South Africa Precision Oncology Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Technology
- 18.4.3. Product & Service
- 18.4.4. Cancer Type
- 18.4.5. Biomarker Type
- 18.4.6. Delivery Model
- 18.4.7. Application
- 18.4.8. End User
- 18.5. Egypt Precision Oncology Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Technology
- 18.5.3. Product & Service
- 18.5.4. Cancer Type
- 18.5.5. Biomarker Type
- 18.5.6. Delivery Model
- 18.5.7. Application
- 18.5.8. End User
- 18.6. Nigeria Precision Oncology Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Technology
- 18.6.3. Product & Service
- 18.6.4. Cancer Type
- 18.6.5. Biomarker Type
- 18.6.6. Delivery Model
- 18.6.7. Application
- 18.6.8. End User
- 18.7. Algeria Precision Oncology Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Technology
- 18.7.3. Product & Service
- 18.7.4. Cancer Type
- 18.7.5. Biomarker Type
- 18.7.6. Delivery Model
- 18.7.7. Application
- 18.7.8. End User
- 18.8. Rest of Africa Precision Oncology Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Technology
- 18.8.3. Product & Service
- 18.8.4. Cancer Type
- 18.8.5. Biomarker Type
- 18.8.6. Delivery Model
- 18.8.7. Application
- 18.8.8. End User
- 19. South America Precision Oncology Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 19.3.1. Technology
- 19.3.2. Product & Service
- 19.3.3. Cancer Type
- 19.3.4. Biomarker Type
- 19.3.5. Delivery Model
- 19.3.6. Application
- 19.3.7. End User
- 19.3.8. Country
- 19.3.8.1. Brazil
- 19.3.8.2. Argentina
- 19.3.8.3. Rest of South America
- 19.4. Brazil Precision Oncology Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Technology
- 19.4.3. Product & Service
- 19.4.4. Cancer Type
- 19.4.5. Biomarker Type
- 19.4.6. Delivery Model
- 19.4.7. Application
- 19.4.8. End User
- 19.5. Argentina Precision Oncology Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Technology
- 19.5.3. Product & Service
- 19.5.4. Cancer Type
- 19.5.5. Biomarker Type
- 19.5.6. Delivery Model
- 19.5.7. Application
- 19.5.8. End User
- 19.6. Rest of South America Precision Oncology Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Technology
- 19.6.3. Product & Service
- 19.6.4. Cancer Type
- 19.6.5. Biomarker Type
- 19.6.6. Delivery Model
- 19.6.7. Application
- 19.6.8. End User
- 20. Key Players/ Company Profile
- 20.1. Agilent Technologies
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. AstraZeneca plc
- 20.3. Bio-Rad Laboratories
- 20.4. Bristol Myers Squibb
- 20.5. Caris Life Sciences
- 20.6. Exact Sciences Corporation
- 20.7. F. Hoffmann-La Roche Ltd.
- 20.8. Foundation Medicine (Roche)
- 20.9. Grail (a subsidiary of Illumina)
- 20.10. Guardant Health
- 20.11. Illumina, Inc.
- 20.12. Invitae Corporation
- 20.13. Merck & Co., Inc.
- 20.14. Myriad Genetics
- 20.15. Natera, Inc.
- 20.16. Novartis AG
- 20.17. Pfizer Inc.
- 20.18. Qiagen N.V.
- 20.19. Roche Diagnostics
- 20.20. Thermo Fisher Scientific
- 20.21. Other Key Players
- 20.1. Agilent Technologies
Note* - This is just tentative list of players. While providing the report, we will cover a greater number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
